---
document_datetime: 2023-09-21 18:23:02
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/sprimeo-hct-epar-public-assessment-report_en.pdf
document_name: sprimeo-hct-epar-public-assessment-report_en.pdf
version: success
processing_time: 1.9712044
conversion_datetime: 2025-12-17 09:14:37.850976
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

ASSESSMENT REPORT FOR Sprimeo HCT International Nonproprietary Name: aliskiren / hydrochlorothiazide Procedure No. EMEA/H/C/002421 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer authorised

●

7 Westferry Circus

Canary Wharf

+44 (0)20 7418 8400

●

London E14 4HB

Facsimile

●

United Kingdom

+44 (0)20 7418 8416

An agency of the European Union

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................3                                 |
|----------------------------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier.................................................................................... 3       |
| 1.2. Steps taken for the assessment of the product ....................................................... 4               |
| 2. Scientific discussion ................................................................................4                 |
| 3.1. Introduction ...................................................................................................... 4 |
| 3.2. Quality aspects .................................................................................................. 5  |
| 3.3. Non-clinical aspects............................................................................................ 5    |
| 3.4. Clinical aspects .................................................................................................. 5 |
| 3.5. Pharmacovigilance.............................................................................................. 5     |
| 3.6. Benefit-Risk assessment ..................................................................................... 6       |
| 3.7. Recommendation ............................................................................................... 6      |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Novartis Europharm Ltd. submitted on 2 December 2010 an application for Marketing Authorisation  to  the  European  Medicines  Agency  (EMA)  for  Sprimeo  HCT,  through  the  centralised procedure under Article  3  (2)  (a)  of  Regulation  (EC)  No  726/2004.  The  eligibility  to  the  centralised procedure was agreed upon by the EMA/CHMP on 23 September 2010.

The  legal  basis  for  this  application  refers  to Article  10(c)  of  Directive  2001/83/EC,  as  amended  relating  to  informed  consent  from  a  marketing  authorisation  holder  Novartis  Europharm  Ltd.  for  an authorised medicinal product Rasilez HCT (EU/1/08/491/001-080).

The application submitted is composed of administrative information, quality, non-clinical and clinical data with a letter from a MAH Novartis Europharm Ltd. allowing the cross reference to relevant quality, non-clinical and/or clinical data.

The applicant applied for the following indication:

'Treatment of essential hypertension in adults.

Sprimeo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.

Sprimeo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.'

## Information on Paediatric requirements

Pursuant  to  Article  7  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision P/31/2009 for the following condition:

-  Essential hypertension.

on the granting of a (product-specific) waiver for

-  Essential hypertension.

## Scientific Advice

The applicant did not seek scientific advice at the CHMP.

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Licensing status

The initial product Rasilez HCT was approved in the EU on 16 January 2009.

The  Rapporteur  and  Co-Rapporteur  appointed  by  the  CHMP  and  the  Rapporteur's  evaluation  team were:

Rapporteur: Daniela Melchiorri Co-Rapporteur:

János Borvendég

## 1.2. Steps taken for the assessment of the product

-  The application was received by the EMA on 2 December 2010.
-  The procedure started on 19 December 2010.
-  The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  21  January 2011.
-  During the meeting on 14-17 February 2011, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Sprimeo HCT on 17 February 2011. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 15 February 2011.

## 2. Scientific discussion

## 2.1. Introduction

This  marketing  authorisation  application  for  Sprimeo  HCT  (aliskiren/hydrochlorothiazide)  has  been submitted by Novartis Europharm Ltd as an informed consent application in accordance with Article 10c of Directive 2001/83/EC, as amended.

The MAH (Novartis Europharm Ltd) for Rasilez HCT, which was authorised on 16 January 2009 and submitted as a fixed combination application under Article 10(b) of Directive 2001/83/EC as amended, provided  consent  to  make  use  of  the  pharmaceutical,  non-clinical  and  clinical  documentation  of  the initial  dossier  of  this  authorised  product  and  any  subsequent  post-marketing  procedures  submitted, assessed and approved.

As a consequence, quality, safety and efficacy of the Sprimeo HCT medicinal product are identical to the up-to-date quality, non-clinical and clinical profile of Rasilez HCT. The application for Sprimeo HCT concerns the identical strengths and pack sizes to those approved for Rasilez HCT and consists of only Module 1. Information on the scientific discussion can be found in the Rasilez HCT CHMP assessment reports and in the European Public Assessment Report (EPAR) published on the EMA website.

Medicinal product no longer authorised

The approved indications are:

'Treatment of essential hypertension in adults.

Sprimeo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.

Sprimeo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.'

<div style=\"page-break-after: always\"></div>

## 2.2. Quality aspects

Since this application is an informed consent of the Rasilez HCT application, the quality data in support of the Sprimeo HCT application are identical to the up-to-date quality data of the Rasilez HCT dossier, which have been assessed and approved (including all post-marketing procedures).

## 2.3. Non-clinical aspects

Since this application is an informed consent of the Rasilez HCT application, the non-clinical data in support of the Sprimeo HCT application are identical to the up-to-date non-clinical data of the Rasilez HCT dossier, which have been assessed and approved (including all post-marketing procedures).

An environmental Risk Assessment has been provided, which is identical to the version submitted as a follow-up measure for Rasilez HCT.

## 2.4. Clinical aspects

Since this application is an informed consent of the Rasilez HCT application, the clinical data in support of the Sprimeo HCT application are identical to the up-to-date clinical data of the Rasilez HCT dossier, which have been assessed and approved (including all post-marketing procedures).

The Applicant has made appropriate commitments to update the product information for Sprimeo HCT post-authorisation in accordance with the outcome of ongoing regulatory procedures for Rasilez HCT.

## User consultation

A justification  for  not  performing  a  full  user  consultation  with  target  patient  groups  on  the  package leaflet has been submitted by the applicant and has been found acceptable for the following reasons:

In  view  of  the  fact  that  a  readability  test  had  been  performed  at  the  time  of  the  original  MAA  for Rasilez HCT and the content of the package leaflet is identical to the latest approved leaflet of Rasilez HCT, no further testing is warranted.

## 2.5. Pharmacovigilance

## PSURs

As  requested  by  the  Applicant  and  agreed  by  the  CHMP,  the  PSUR  cycle  of  this  informed  consent application will be aligned with the PSUR cycle for the reference product, Rasilez HCT, unless otherwise specified.

Medicinal product no longer authorised

## Detailed description of the pharmacovigilance system (DDPS)

The  CHMP  considered  that  the  Pharmacovigilance  system  as  described  by  the  applicant  fulfils  the legislative requirements.

## Risk Management Plan

The Applicant submitted a risk management plan (version 6) identical with that for Rasilez HCT. The Applicant has made a post-authorisation commitment to provide an updated RMP version based on the outcome of the ongoing assessments of the latest RMP for Rasilez HCT.

<div style=\"page-break-after: always\"></div>

The CHMP, having considered the data submitted in the application, is of the opinion that no additional risk minimisation activities are required beyond those included in the product information.

## 2.6. Benefit-Risk assessment

This  marketing  authorisation  application  for  Sprimeo  HCT  (aliskiren/hydrochlorothiazide)  has  been submitted by Novartis Europharm Ltd as an informed consent application in accordance with Article 10c of Directive 2001/83/EC, as amended.

The MAH (Novartis Europharm Ltd) for Rasilez HCT, which was authorised on 16 January 2009 and submitted as a fixed combination application under Article 10(b) of Directive 2001/83/EC as amended, provided  consent  to  make  use  of  the  pharmaceutical,  non-clinical  and  clinical  documentation  of  the initial  dossier  of  this  authorised  product  and  any  subsequent  post-marketing  procedures  submitted, assessed and approved.

As a consequence, quality, safety and efficacy of the Sprimeo HCT medicinal product are identical to the up-to-date quality, non-clinical and clinical profile of Rasilez HCT. The application for Sprimeo HCT concerns the identical strengths and pack sizes to those approved for Rasilez HCT and consists of only Module 1. Information on the scientific discussion can be found in the Rasilez HCT CHMP assessment reports and in the European Public Assessment Report (EPAR) published on the EMA website.

Based on the assessment of all available data,  the CHMP concluded that the benefit/risk  balance is positive for the following proposed indications:

'Treatment of essential hypertension in adults.

Sprimeo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.

Sprimeo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.'

## 2.7. Recommendation

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considered by consensus that the benefit/risk balance of Sprimeo HCT in the treatment of essential hypertension was favourable and therefore recommended the granting of the marketing authorisation.

Medicinal product no longer authorised